Authorization

The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs

The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves.

The biggest biotech news of the week came in the form of approval for Biogen Inc.'s (NASDAQ:BIIB) Alzheimer's drug Aduhelm. The approval polarized the scientific community. The stock, which at one point tacked on about 64% on the day of the approval, ended the week up about 40%.

Alexion Pharmaceuticals, Inc.'s(NASDAQ:ALXN) Ultomiris received label expansion to treat paroxysmal nocturnal hemoglobinuria in children and adolescents.

Among other approvals that came through during the week were label expansion for Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) triple combo cystic fibrosis drug Trikafta and Pfizer Inc.'s (NYSE:PFE) 20-valent pneumococcal conjugate vaccine.

Vertex, however, had a mixed week, as it announced the shelving of a mid-stage study of a drug for a rare, inherited lung disease.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2021    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728293031